Christopher Lieu, MD
University of Colorado, Denver · Criterium Inc., d.b.a. Academic GI Cancer Consortium (AGICC) · University of Colorado School of Medicine Anschutz Medical Campus
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Christopher Lieu, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:07 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03475004 · Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal CancerUniversity of Colorado, Denver · completed · Colorectal Cancer, Metastatic Cancer · principal investigator
- Ph2NCT02638909 · Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal MalignanciesCriterium, Inc. · terminated · Colorectal Adenocarcinoma, Cholangiocarcinoma, Pancreatic Adenocarcinoma · principal investigator
- N/ANCT02151123 · Metabiomics Colon Cancer Clinical Research StudyMetabiomics Corp · withdrawn · Colonic Neoplasms · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:07 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in pancreatic cancer.